A significant reduction in IL-10-producing, tumour-infiltrating DCs and lung cancer incidence was evident in mice harbouring Gal1-silenced tumour cells, emphasizing that Gal1 is a potential target for the development of lung cancer therapeutics [55]. The gene discussed is IL10; the disease is neoplasm.